Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Abstract Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advance...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0335-9 |